Genpharmasec
BSE: GENPHARMA · Trading & Distributors
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Genpharmasec's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Genpharmasec Limited is an Indian company primarily engaged in the distribution and marketing of diagnostic equipment, medical devices, and pharmaceutical products. It serves as a bridge between global medical technology manufacturers and the domestic Indian healthcare infrastructure.
Business Model
The company generates revenue through the procurement and supply of high-end medical instruments to hospitals and laboratories. It is also exploring diversification into the technology and financial services sectors to supplement its core healthcare distribution business.
Management Commentary
Management is focused on strengthening the company's presence in the medical diagnostic market through strategic partnerships and the expansion of its product portfolio.
Growth Outlook
Growth is expected to be driven by the expansion of the company's medical product portfolio and its efforts to integrate global medical technology into the Indian market.
Key Risks
- Regulatory Risk. Changes in healthcare regulations and medical device import policies could adversely impact the company's supply chain and margins.
- Market Competition. The medical distribution sector in India is highly competitive, which may pressure pricing and profitability.
- Diversification Risk. Venturing into technology and financial services may distract from core operations and introduce risks outside the company's primary expertise.
- Dependency on Principals. The company's business model relies heavily on maintaining successful distribution partnerships with global medical technology manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Genpharmasec and 5,000+ companies — free.
Key Metrics
REVENUE
₹140 Cr
TTM · consolidated
NET PROFIT
₹5 Cr
TTM · consolidated
EPS
₹0.08
TTM · consolidated
RETURN ON EQUITY
7.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.6%
TTM · consolidated
P/E
13.0x
Q4 FY26 · consolidated
EV/EBITDA
9.5x
Q4 FY26 · consolidated
EBITDA MARGIN
6.2%
TTM · consolidated
NET PROFIT MARGIN
2.4%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.5x
Q4 FY26 · consolidated
Peers · Trading & Distributors
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
GenpharmasecGENPHARMA | ₹57 Cr | 12.88 | 10.29 | 315.1% | 6.2% | 7.0% | 8.6% | -46.9% |
Veritas (India)VERITAS | ₹445 Cr | 8.63 | 7.06 | -24.1% | 3.9% | 1.9% | 2.7% | -55.4% |
Kothari ProductsKOTHARIPRO | ₹407 Cr | 179.58 | -12.12 | -18.3% | -5.1% | -0.2% | -2.3% | -9.8% |
Rotographics (India) LimitedRGIL | ₹404 Cr | 94.62 | 326.54 | 4987.7% | 3.0% | 12.6% | 17.2% | — |
Polo Queen Industrial and Fintech LimitedPQIF | ₹333 Cr | 141.71 | 64.71 | -5.7% | 7.0% | 1.3% | 2.5% | -79.1% |
Constronics Infra Ltd.CONSTRONIC | ₹61 Cr | — | — | — | 5.5% | — | — | -24.7% |
As of Q4 FY26
Financials
Genpharmasec
BSE: GENPHARMA · Trading & Distributors
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Genpharmasec's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Genpharmasec Limited is an Indian company primarily engaged in the distribution and marketing of diagnostic equipment, medical devices, and pharmaceutical products. It serves as a bridge between global medical technology manufacturers and the domestic Indian healthcare infrastructure.
Business Model
The company generates revenue through the procurement and supply of high-end medical instruments to hospitals and laboratories. It is also exploring diversification into the technology and financial services sectors to supplement its core healthcare distribution business.
Management Commentary
Management is focused on strengthening the company's presence in the medical diagnostic market through strategic partnerships and the expansion of its product portfolio.
Growth Outlook
Growth is expected to be driven by the expansion of the company's medical product portfolio and its efforts to integrate global medical technology into the Indian market.
Key Risks
- Regulatory Risk. Changes in healthcare regulations and medical device import policies could adversely impact the company's supply chain and margins.
- Market Competition. The medical distribution sector in India is highly competitive, which may pressure pricing and profitability.
- Diversification Risk. Venturing into technology and financial services may distract from core operations and introduce risks outside the company's primary expertise.
- Dependency on Principals. The company's business model relies heavily on maintaining successful distribution partnerships with global medical technology manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Genpharmasec and 5,000+ companies — free.
Key Metrics
REVENUE
₹140 Cr
TTM · consolidated
NET PROFIT
₹5 Cr
TTM · consolidated
EPS
₹0.08
TTM · consolidated
RETURN ON EQUITY
7.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.6%
TTM · consolidated
P/E
13.0x
Q4 FY26 · consolidated
EV/EBITDA
9.5x
Q4 FY26 · consolidated
EBITDA MARGIN
6.2%
TTM · consolidated
NET PROFIT MARGIN
2.4%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.5x
Q4 FY26 · consolidated
Peers · Trading & Distributors
As of Q4 FY26